Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 5
2009 3
2010 3
2011 3
2012 6
2013 12
2014 3
2015 7
2016 5
2017 2
2018 3
2019 5
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Role of PARP inhibitors in cancer biology and therapy.
Davar D, Beumer JH, Hamieh L, Tawbi H. Davar D, et al. Curr Med Chem. 2012;19(23):3907-21. doi: 10.2174/092986712802002464. Curr Med Chem. 2012. PMID: 22788767 Free PMC article. Review.
ATM protein is deficient in over 40% of lung adenocarcinomas.
Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, Siegfried JM, Conrads TP, Smith NR, O'Connor MJ, Pierce AJ, Bakkenist CJ. Villaruz LC, et al. Oncotarget. 2016 Sep 6;7(36):57714-57725. doi: 10.18632/oncotarget.9757. Oncotarget. 2016. PMID: 27259260 Free PMC article.
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM. Lee DH, et al. PLoS One. 2015 Aug 6;10(8):e0134426. doi: 10.1371/journal.pone.0134426. eCollection 2015. PLoS One. 2015. PMID: 26247786 Free PMC article.
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Tan AR, Chan N, Kiesel BF, Stein MN, Moss RA, Malhotra J, Aisner J, Shah M, Gounder M, Lin H, Kane MP, Lin Y, Ji J, Chen A, Beumer JH, Mehnert JM. Tan AR, et al. Cancer Chemother Pharmacol. 2022 Jan;89(1):49-58. doi: 10.1007/s00280-021-04350-x. Epub 2021 Oct 20. Cancer Chemother Pharmacol. 2022. PMID: 34669023 Free PMC article. Clinical Trial.
Phase I study of veliparib in combination with gemcitabine.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Stoller R, et al. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2. Cancer Chemother Pharmacol. 2017. PMID: 28770300 Free PMC article. Clinical Trial.
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Malhotra MK, Pahuja S, Kiesel BF, Appleman LJ, Ding F, Lin Y, Tawbi HA, Stoller RG, Lee JJ, Belani CP, Chen AP, Giranda VL, Shepherd SP, Emens LA, Ivy SP, Chu E, Beumer JH, Puhalla S. Malhotra MK, et al. Breast Cancer Res Treat. 2023 Apr;198(3):487-498. doi: 10.1007/s10549-023-06889-0. Epub 2023 Feb 28. Breast Cancer Res Treat. 2023. PMID: 36853577 Free PMC article. Clinical Trial.
56 results